4-(3-Phenoxypropoxy)phenol | 30311-36-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 4-(3-Phenoxypropoxy)phenol
• 英文别名: 4-(3-methoxypropoxy)phenol
• CAS: 30311-36-5
• 化学式: C₁₀H₁₄O₃
• 分子量: 182.219
• InChiKey: JHTVLTCTJRDPSF-UHFFFAOYSA-N

物化性质

• 沸点：
  302.4±17.0 °C(Predicted)
• 密度：
  1.086±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(3-Phenoxypropoxy)phenol 、 N-[5-(4-iodo-2,6-dimethylphenyl)thiazol-2-yl]isonicotinamide 在 copper(l) iodide 、 iron(III)-acetylacetonate 、 potassium carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 12.0h， 以19%的产率得到N-(5-{4-[4-(3-methoxypropoxy)phenoxy]-2,6-dimethylphenyl}thiazol-2-yl)isonicotinamide
  参考文献：
  名称：

  Discovery of T-1101 tosylate as a first-in-class clinical candidate for Hec1/Nek2 inhibition in cancer therapy

  摘要：

  Highly expressed in cancer 1 (Hec1) plays an essential role in mitosis and is correlated with cancer formation, progression, and survival. Phosphorylation of Hec1 by Nek2 kinase is essential for its mitotic function, thus any disruption of Hec1/Nek2 protein-protein interaction has potential for cancer therapy. We have developed T-1101 tosylate (9j tosylate, 9j formerly known as TAI-95), optimized from 4-aryl-N-pyridinylcarbonyl-2-aminothiazole of scaffold 9 by introducing various C-4' substituents to enhance potency and water solubility, as a first-in-class oral clinical candidate for Hec1 inhibition with potential for cancer therapy. T-1101 has good oral absorption, along with potent in vitro antiproliferative activity (IC50: 14.8-21.5 nM). It can achieve high concentrations in Huh-7 and MDA-MB-231 tumor tissues, and showed promise in antitumor activity in mice bearing human tumor xenografts of liver cancer (Huh-7), as well as of breast cancer (BT474, MDA-MB-231, and MCF7) with oral administration. Oral co-administration of T-1101 halved the dose of sorafenib (25 mg/kg to 12.5 mg/kg) required to exhibit comparable in vivo activity towards Huh-7 xenografts. Cellular events resulting from Hec1/Nek2 inhibition with T-1101 treatment include Nek2 degradation, chromosomal misalignment, and apoptotic cell death. A combination of T-1101 with either of doxorubicin, paclitaxel, and topotecan in select cancer cells also resulted in synergistic effects. Inactivity of T-1101 on non-cancerous cells, a panel of kinases, and hERG demonstrates cancer specificity, target specificity, and cardiac safety, respectively. Subsequent salt screening showed that T-1101 tosylate has good oral AUC (62.5 mu M.h), bioavailability (F = 77.4%), and thermal stability. T-1101 tosylate is currently in phase I clinical trials as an orally administered drug for cancer therapy. (c) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2020.112118
• 作为产物：
  描述：

  1-溴-3-甲氧基丙烷 、 4-甲氧基苯酚 在 sodium hydride 作用下， 生成 4-(3-Phenoxypropoxy)phenol
  参考文献：
  名称：

  Kirmse, Wolfgang; Lelgemann, Rudolf; Friedrich, Klaus, Chemische Berichte, 1991, vol. 124, # 8, p. 1853 - 1863

  摘要：

  DOI：

文献信息

• [EN] NOVEL OXA-AND AZA-TRICYCLIC 4-PYRIDONE-3-CARBOXYLIC ACID FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION<br/>[FR] NOUVEL ACIDE 4-PYRIDONE-3-CARBOXYLIQUE OXA-ET AZA-TRICYCLIQUE POUR LE TRAITEMENT ET LA PROPHYLAXIE D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B
  申请人：PHARMARESOURCES SHANGHAI CO LTD

  公开号：WO2019169539A1

  公开（公告）日：2019-09-12

  Provided herein are oxa- and aza-tricyclic 4-pyridone-3-carboxylic acid compounds, their manufacture, pharmaceutical compositions comprising them, and their use as medicaments for inhibiting HBsAg secretion and HBV DNA production, and for treatment and/or prophylaxis of hepatitis B infection.

  本文提供了氧杂三环4-吡啶酮-3-羧酸化合物，它们的制备方法，包含它们的药物组合物，以及它们作为抑制HBsAg分泌和HBV DNA产生的药物，以及用于治疗和/或预防乙型肝炎感染的用途。
• THERMALLY CONDUCTIVE MATERIAL, DEVICE PROVIDED WITH THERMALLY CONDUCTIVE LAYER, THERMALLY CONDUCTIVE MATERIAL FORMATION COMPOSITION, DISC-SHAPED LIQUID CRYSTAL COMPOUND
  申请人：FUJIFILM Corporation

  公开号：EP3653660A1

  公开（公告）日：2020-05-20

  The present invention provides a thermally conductive material having excellent thermal conductivity. Furthermore, the present invention provides a device with a thermally conductive layer that has a thermally conductive layer containing the thermally conductive material and a composition for forming a thermally conductive material that is used for forming the thermally conductive material. The thermally conductive material according to an embodiment of the present invention contains a cured substance of a disk-like compound, which has one or more reactive functional groups selected from the group consisting of a hydroxyl group, a carboxylic acid group, a carboxylic acid anhydride group, an amino group, a cyanate ester group, and a thiol group, and a crosslinking compound which has a group reacting with the reactive functional groups.

  本发明提供了一种具有优异导热性能的导热材料。此外，本发明还提供了一种具有导热层的设备，该设备具有包含该导热材料的导热层和用于形成导热材料的导热材料组合物。根据本发明一个实施例的导热材料含有盘状化合物的固化物，该固化物具有一个或多个反应性官能团，这些反应性官能团选自由羟基、羧酸基、羧酸酐基、氨基、氰酸酯基和硫醇基组成的组，以及具有与反应性官能团反应的基团的交联化合物。
• THERMALLY CONDUCTIVE MATERIAL, DEVICE WITH THERMALLY CONDUCTIVE LAYER, COMPOSITION FOR FORMING THERMALLY CONDUCTIVE MATERIAL, AND DISK-LIKE LIQUID CRYSTAL COMPOUND
  申请人：FUJIFILM Corporation

  公开号：US20200148931A1

  公开（公告）日：2020-05-14

  The present invention provides a thermally conductive material having excellent thermal conductivity. Furthermore, the present invention provides a device with a thermally conductive layer that has a thermally conductive layer containing the thermally conductive material and a composition for forming a thermally conductive material that is used for forming the thermally conductive material. The thermally conductive material according to an embodiment of the present invention contains a cured substance of a disk-like compound, which has one or more reactive functional groups selected from the group consisting of a hydroxyl group, a carboxylic acid group, a carboxylic acid anhydride group, an amino group, a cyanate ester group, and a thiol group, and a crosslinking compound which has a group reacting with the reactive functional groups.
• Kirmse, Wolfgang; Lelgemann, Rudolf; Friedrich, Klaus, Chemische Berichte, 1991, vol. 124, # 8, p. 1853 - 1863
  作者：Kirmse, Wolfgang、Lelgemann, Rudolf、Friedrich, Klaus

  DOI：——

  日期：——
• Discovery of T-1101 tosylate as a first-in-class clinical candidate for Hec1/Nek2 inhibition in cancer therapy
  作者：Shih-Hsien Chuang、Ying-Shuan E. Lee、Lynn Y.L. Huang、Chi-Kuan Chen、Chun-Liang Lai、Yu-Hsiang Lin、Ju-Ying Yang、Sheng-Chuan Yang、Lien-Hsiang Chang、Ching-Hui Chen、Chia-Wei Liu、Her-Sheng Lin、Yi-Ru Lee、Kuan Pin Huang、Kuo Chu Fu、Hsueh-Min Jen、Jun-Yu Lai、Pei-Shiou Jian、Yu-Chuan Wang、Wen-Yun Hsueh、Pei-Yi Tsai、Wan-Hua Hong、Chia-Chi Chang、Diana ZC. Wu、Jinn Wu、Meng-Hsin Chen、Kuo-Ming Yu、Ching Yuh Chern、Jia-Ming Chang、Johnson Y.N. Lau、Jiann-Jyh Huang

  DOI：10.1016/j.ejmech.2020.112118

  日期：2020.4

  Highly expressed in cancer 1 (Hec1) plays an essential role in mitosis and is correlated with cancer formation, progression, and survival. Phosphorylation of Hec1 by Nek2 kinase is essential for its mitotic function, thus any disruption of Hec1/Nek2 protein-protein interaction has potential for cancer therapy. We have developed T-1101 tosylate (9j tosylate, 9j formerly known as TAI-95), optimized from 4-aryl-N-pyridinylcarbonyl-2-aminothiazole of scaffold 9 by introducing various C-4' substituents to enhance potency and water solubility, as a first-in-class oral clinical candidate for Hec1 inhibition with potential for cancer therapy. T-1101 has good oral absorption, along with potent in vitro antiproliferative activity (IC50: 14.8-21.5 nM). It can achieve high concentrations in Huh-7 and MDA-MB-231 tumor tissues, and showed promise in antitumor activity in mice bearing human tumor xenografts of liver cancer (Huh-7), as well as of breast cancer (BT474, MDA-MB-231, and MCF7) with oral administration. Oral co-administration of T-1101 halved the dose of sorafenib (25 mg/kg to 12.5 mg/kg) required to exhibit comparable in vivo activity towards Huh-7 xenografts. Cellular events resulting from Hec1/Nek2 inhibition with T-1101 treatment include Nek2 degradation, chromosomal misalignment, and apoptotic cell death. A combination of T-1101 with either of doxorubicin, paclitaxel, and topotecan in select cancer cells also resulted in synergistic effects. Inactivity of T-1101 on non-cancerous cells, a panel of kinases, and hERG demonstrates cancer specificity, target specificity, and cardiac safety, respectively. Subsequent salt screening showed that T-1101 tosylate has good oral AUC (62.5 mu M.h), bioavailability (F = 77.4%), and thermal stability. T-1101 tosylate is currently in phase I clinical trials as an orally administered drug for cancer therapy. (c) 2020 Elsevier Masson SAS. All rights reserved.